Whitehawk Therapeutics Inc

NASDAQ:WHWK

Biotechnology

Healthcare
$3.13 +1.42%

+$0.06 today

Market cap
$184.70M
Beta
0.77
P/E (TTM)
-2.6
EPS (TTM)
-$1.67
52W Low $1.57High $5.50

Volume 0.28M

Average 0.31M

WHWK Inventory

Cash effect of the change in inventory; building inventory consumes cash.

Whitehawk Therapeutics IncNASDAQ: WHWK

Inventory · Q4 FY2025 · quarter ended Dec 2025

Inventory outflow shrinks to $0

Q4 FY2025 inventory was $0, compared with $158K a year earlier. Trailing-twelve-month inventory was $170K.

Context

  • Inventory amounted to 2.4% of revenue in FY2025, down 1.9 pp from a year earlier.
  • Inventory increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly inventory holds near $0 or moves back toward the trailing-twelve-month quarterly average of $42.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
$0— QoQ
Last fiscal yearDec 2025
$170K-84.8% YoY
LTMDec 2025
$170K-84.8% YoY
Inventory past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-84.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Inventory history

USD · from the cash flow

Latest · FY2025
170K USD
Year-over-year change
-84.8%

Inventory vs competitors

How WHWK compares with its peers on the latest reported figures

  • Peers report in different currencies, so inventory is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -84.8% is the 2nd highest of 3, against a peer median of +700.3%.
  • Inventory amounts to 2.4% of revenue for WHWK, versus a peer median of 0.0%.
WHWK Competitors
Inventory for WHWK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WHWKWhitehawk Therapeutics IncLTM Dec 2025$170K USD-84.8%—2.4%
MGNXMacroGenics, Inc.LTM Mar 2026$73K USD-99.4%—0.0%
CLNNClene Inc.LTM Mar 2026$16K USD+1500.0%—11.9%
IMMXImmix Biopharma, Inc.LTM Mar 2026$0 USD———
OVIDOvid Therapeutics Inc.LTM Mar 2026$0 USD——0.0%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
PLRXPliant Therapeutics, Inc.LTM Mar 2026$0 USD———
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$0 CAD———
CNTXContext Therapeutics Inc.LTM Mar 2026$0 USD———
Peer median (excluding WHWK) —+700.3%—0.0%

Competitors are the stored peer set for WHWK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(110.09M)(60.51M)(65.77M)(63.69M)(20.6M)
Depreciation & Amortization105K159K169K193K79K
Deferred Income Tax00000
Stock-Based Compensation2.11M9.64M11.95M10.84M9.87M
Change in Working Capital3.96M(5.04M)(3.27M)3.72M1.93M
Accounts Receivables14.15M(1.86M)(3.63M)(415K)(1M)
Inventory0(1.86M)(3.27M)1.12M170K
Accounts Payables00003.92M
Other Working Capital(10.19M)(1.32M)3.62M3.02M(1.16M)
Other Non-Cash Items81.5M6.11M(2.75M)(10.61M)(78.77M)
Operating Cash Flow(22.42M)(49.64M)(59.66M)(59.55M)(97.43M)
Capital Expenditures(46K)(444K)(3.97M)(1.65M)(552K)
Acquisitions (Net)25.2M000101.29M
Purchases of Investments0(145.19M)(64.44M)(36.48M)(148.69M)
Sales of Investments012.75M151.62M63.34M59.85M
Other Investing Activities00000
Investing Cash Flow25.15M(132.89M)83.21M25.2M11.89M
Debt Repayment00000
Common Stock Issued155M72.5M0130K100M
Common Stock Repurchased00000
Dividends Paid(4.41M)0000
Other Financing Activities(8.78M)120K326K(16K)(5.63M)
Financing Cash Flow141.8M72.62M326K130K94.38M
Effect of Forex Changes000064K
Net Change in Cash144.53M(109.91M)23.87M(34.22M)8.9M
Free Cash Flow(22.47M)(50.08M)(63.64M)(61.2M)(97.99M)

Whitehawk Therapeutics Inc

NASDAQ:WHWK

Intrinsic Alpha fair value

Locked

Current Price

$3.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.